

GENETRONICS BIOMEDICAL LTD  
Form SC 13G  
March 21, 2001

1

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

-----  
SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)

(Amendment No. \_\_\_\_)(1)

Genetronics Biomedical, Ltd.

-----  
(Name of Issuer)

Common Stock

-----  
(Title of Class of Securities)

371916 10 7

-----  
(CUSIP Number)

December 31, 1998

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

2

Edgar Filing: GENETRONICS BIOMEDICAL LTD - Form SC 13G

CUSIP No. 371916 10 7

13G

Page 2 of 7 Pages

1. NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)  
Johnson & Johnson 22-1024240

---

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  
(a)   
(b)

---

3. SEC USE ONLY

---

4. CITIZENSHIP OR PLACE OF ORGANIZATION  
New Jersey

---

5. SOLE VOTING POWER	0
6. SHARED VOTING POWER	2,242,611
7. SOLE DISPOSITIVE POWER	0
8. SHARED DISPOSITIVE POWER	2,242,611

---

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,242,611

---

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

---

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
8.2%

---

12. TYPE OF REPORTING PERSON\*  
CO

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

3

CUSIP No. 371916 10 7

13G

Page 3 of 7 Pages

1. NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)  
Johnson & Johnson Development Corporation 22-2007137

---

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  
(a)   
(b)

Edgar Filing: GENETRONICS BIOMEDICAL LTD - Form SC 13G

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

New Jersey

5. SOLE VOTING POWER 0  
NUMBER OF SHARES

BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 6. SHARED VOTING POWER 2,242,611

7. SOLE DISPOSITIVE POWER 0

8. SHARED DISPOSITIVE POWER 2,242,611

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,242,611

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*  
[ ]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

8.2%

12. TYPE OF REPORTING PERSON\*

CO

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

4  
CUSIP No. 371916 10 7 13G Page 4 of 7 Pages

ITEM 1(a). NAME OF ISSUER:

Genetronics Biomedical, Ltd.

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

11199 Sorrento Valley Road  
San Diego, CA 92121-1334

ITEM 2(a). NAME OF PERSON FILING:

Johnson & Johnson ("J&J")  
Johnson & Johnson Development Corporation ("JJDC")

ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

One Johnson & Johnson Plaza  
New Brunswick, NJ 08933

ITEM 2(c). CITIZENSHIP:

# Edgar Filing: GENETRONICS BIOMEDICAL LTD - Form SC 13G

J&J and JJDC are both New Jersey corporations

ITEM 2(d). TITLE OF CLASS OF SECURITIES:

Common Stock, no par value per share

Item 2(e). CUSIP Number:

371916 10 7

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a)  Broker or dealer registered under Section 15 of the Exchange Act.
- (b)  Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c)  Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d)  Investment company as defined in Section 8 of the Investment Company Act.
- (e)  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
- (f)  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

5

CUSIP No. 371916 10 7

13G

Page 5 of 7 Pages

- (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i)  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
- (j)  Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

N/A

ITEM 4. OWNERSHIP:

(a) Amount beneficially owned:

J&J	2,242,611
JJDC	2,242,611

(b) Percent of class:

J&J	8.2%
JJDC	8.2%

(c) Number of shares as to which such person has:

Edgar Filing: GENETRONICS BIOMEDICAL LTD - Form SC 13G

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote:

J&J	2,242,611
JJDC	2,242,611

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of:

J&J	2,242,611
JJDC	2,242,611

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of a class of securities, check the following [ ].

N/A

6

CUSIP No. 371916 10 7 13G Page 6 of 7 Pages

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

N/A

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

N/A

ITEM 8. IDENTIFICATION OF MEMBERS OF THE GROUP:

N/A

ITEM 9. NOTICE OF DISSOLUTION OF A GROUP:

N/A

ITEM 10. CERTIFICATION:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

7

CUSIP No. 371916 10 7 13G Page 7 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and

Edgar Filing: GENETRONICS BIOMEDICAL LTD - Form SC 13G

correct.

Dated: March 21, 2001  
-----

JOHNSON & JOHNSON

By /s/ Michael H. Ullmann  
-----

Name: Michael H. Ullmann

Title: Secretary

Dated: March 21, 2001  
-----

JOHNSON & JOHNSON DEVELOPMENT  
CORPORATION

By /s/ Eric B. Jung  
-----

Name: Eric B. Jung

Title: Secretary